Table 5.
Therapeutic approaches for the development and use of SPM mimetics in cancer treatments.
Disadvantages | Advantages | |||
---|---|---|---|---|
SPMs | Native | Short half-life | Biological activities | |
Analogs | Short half-life | Increased Stability | ||
Biological activities | ||||
Receptor agonists | Small molecules | Short half-life | Increased Stability | |
Easy to develop | ||||
Biological activities | ||||
Monoclonal antibodies | Manufacturing costs | Long exposure for chronic disease | ||
Easy to develop | ||||
Specificity and selectivity |